Neuropeptide Y Y2 Receptor (NPY2R): the presynaptic autoreceptor behind satiety and the gut–brain axis

1.  What the Y2 receptor is — in plain language

Neurons talk to each other with chemical messengers. Some receptors sit on the receiving cell and pass a message onward. The Y2 receptor mostly does something cleverer: it sits on the sending cell's own terminal as an autoreceptor, and when it detects that its neuron has already released plenty of messenger, it tells that neuron to ease off. It is negative feedback built into the wiring — the nervous system listening to itself and staying in balance.

Its natural keys are two closely related 36-amino-acid peptides. Neuropeptide Y is among the most abundant peptides in the mammalian brain, first isolated from porcine brain by Kazuhiko Tatemoto and Viktor Mutt in 1982²; its name comes from a tyrosine (single-letter Y) at each end of the chain. Peptide YY is its cousin, made in the gut. Both belong to the pancreatic-polypeptide family and share a hairpin "PP-fold." The Y2 receptor is unusual in that it prefers the C-terminal fragments of these peptides — chiefly PYY3-36 and NPY13-36 — rather than the full intact chains, a preference that turns out to matter a great deal downstream.

2.  The gut–brain satiety conversation

Here is where the Y2 receptor becomes fascinating. When you finish a meal, L-cells in the lining of the lower gut release PYY in proportion to the calories you just ate. In the bloodstream an enzyme, dipeptidyl peptidase-4 (DPP-4), clips the first two residues off PYY(1-36) to make PYY3-36 — and that small edit sharpens the peptide's aim squarely at the Y2 receptor. PYY3-36 travels to the brain's appetite hub, the hypothalamic arcuate nucleus, where it engages Y2 autoreceptors on the very neurons (the NPY/AgRP neurons) that otherwise drive hunger — and quiets them. The felt result is fullness.

In 2002, Rachel Batterham and colleagues showed in Nature that giving PYY3-36 at a natural, meal-sized level reduced food intake in both rodents and people, and traced the effect to the Y2 receptor³. It was a vivid demonstration that a hormone made in the gut can speak directly to the brain's hunger circuitry. The same thread helps explain a long-standing puzzle: why some people lose their appetite after bariatric surgery. Procedures such as Roux-en-Y raise circulating PYY and other gut hormones, so the brain hears a stronger, earlier "enough" signal.

3.  The NPY receptor family — a division of labour

NPY and PYY act through a small family of receptors, each with its own accent. Reading them side by side shows why Y2 stands apart — it is the feedback-and-satiety member.

A fifth subtype, y6, is non-functional in humans, so the working human family is Y1, Y2, Y4 and Y5.

4.  Where the Y2 receptor lives

The Y2 receptor is broadly distributed, which is why its influence reaches well beyond appetite:

• Hippocampus — abundant here, where NPY signalling helps steady excitability; hippocampal NPY has a well-documented calming, anticonvulsant character.
• Hypothalamus — especially the arcuate nucleus, the seat of the PYY3-36 satiety action described above.
• Sympathetic neurons — on the terminals of the sympathetic nervous system, where the autoreceptor tempers noradrenaline and NPY co-release, supporting cardiovascular balance.
• Periphery — in the gut and vasculature, tying the receptor into digestion and local blood-flow control.

Genetically, human NPY2R encodes a 381-amino-acid, seven-transmembrane receptor and maps to chromosome 4q32.1, close to the Y1 receptor gene⁴. Like its relatives it couples through G_i/o proteins to lower intracellular cAMP and damp calcium entry at the nerve terminal — the molecular basis of its "ease off" message.

5.  Why it matters — the open frontier

Because the Y2 receptor carries a natural satiety signal, activating it works with the body's own regulation rather than overriding it. That is the appeal for metabolic health: a long-acting PYY3-36-like Y2 agonist could reinforce the fullness signal the gut already sends after eating, and several groups are pairing Y2 agonism with GLP-1 agonism to let two complementary gut-hormone pathways add up. The unsolved part is delivery and durability — PYY3-36 is a small, fragile peptide, easily trimmed further by the very proteases that made it, and easily unfolded or oxidised during manufacture and storage. Keeping such a molecule intact from synthesiser to syringe is a genuine frontier in its own right.

6.  Where Panacea Bio Chem works

Panacea Bio Chem researches this sphere from the preservation side: its ongoing work treats the fragile signalling peptides of the NPY/PYY family — molecules whose very identity, like PYY3-36, is defined by a precise proteolytic edit — as a case study in protecting sequence integrity through synthesis, drying, storage and reconstitution. The direction its research points is a peptide that reaches the patient exactly as it left the bench.

Several Panacea technologies bear on that goal. Cryolapse™ — gentle cryogenic freeze-drying → removes water without the flash-boiling that can shear a delicate chain; TgShift™ — raising the glass-transition ceiling → keeps the dried cake stable; and OxyDeplete™ — headspace oxygen removal → guards oxidation-prone residues. The Lyoprester® dual-chamber cartridge → then lets the dried peptide meet its diluent cleanly, at the point of use, with the whole choreography watched in real time by S3Pulse™ — the process brain →. The exact procedures, parameters and sequences remain proprietary to Panacea Bio Chem and are not disclosed; the outline is here, the recipe stays behind the door.

7.  Potential application fields

• Metabolic health & appetite support — Y2 agonists that reinforce the body's own post-meal satiety signal, on their own or paired with GLP-1 pathways.
• Neuroscience research tools — subtype-selective Y2 ligands to map presynaptic feedback in hippocampal and hypothalamic circuits.
• Excitability & calm — exploring the hippocampal NPY/Y2 system's steadying, anticonvulsant character.
• Cardiovascular balance — the sympathetic-terminal autoreceptor as a lever on noradrenaline/NPY co-release.
• Bone biology — the well-studied link between Y2 signalling and bone-forming activity (where blocking Y2 signalling, rather than activating it, raises bone formation in animal models)^6,7.
• Delivery science — stabilised, long-acting formulations that keep a DPP-4-shaped peptide intact all the way to the patient.

Frequently asked

Trending in the field

References & further reading

1. Parker SL, Balasubramaniam A. Neuropeptide Y Y2 receptor in health and disease. Br J Pharmacol, 2008.
2. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y — a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, 1982.
3. Batterham RL, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418, 650–654 (2002). PMID 12167864 · DOI 10.1038/nature00887.
4. NPY2R neuropeptide Y receptor Y2 (Homo sapiens). NCBI Gene 4887.
5. Li Z, et al. Therapeutic potential of modulating endogenous PYY expression for controlling overweight and obesity. Front Nutr, 2026.
6. Allison SJ, et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res, 2009.
7. Seldeen KL, et al. Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density. Neuropeptides, 2018.